A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

Trial Details

NCT ID

NCT07321106

Phase

PHASE1

Sponsor

Cartography Biosciences

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

• CBI-1214

Locations (sample)

• Los Angeles, California, United States|34.05223,-118.24368
• Grand Rapids, Michigan, United States|42.96336,-85.66809
• San Antonio, Texas, United States|29.42412,-98.49363
• Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

• The main inclusion criteria include but are not limited to the following:
• Participant with MSS/MSI-L CRC, who has exhausted at least one prior line of standard systemic therapy for their current malignancy.
• Participant with genomic aberrations, including but not limited to BRAFV600E mutations and HER2 amplifications, for which FDA-approved targeted the…
• Have received prior treatment with applicable FDA-approved targeted therapies AND

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.